News | September 02, 2022
Ashland to expand bioresorbable polymers capacity in Ireland
The capital expansion program commenced in June 2022 and is expected to complete in 2024
The capital expansion program commenced in June 2022 and is expected to complete in 2024
To mark the occasion, Integrated Pharmaceutical Database Management System 2.0 (IPDMS 2.0), an integrated responsive cloud-based application developed by NPPA with technical support from C-DAC will be launched
The ninth acquisition since 2018
The company has received 1 (ONE) observation on Form 483 with respect to ANDA filed for the product to be manufactured at the said Facility.
First and only PARP inhibitor to improve invasive disease-free survival, the primary endpoint, and overall survival, a key secondary endpoint of the OlympiA trial, in these patients
Celanese to conduct research, prototype development and characterization of a refillable contraceptive technology with award from the Bill & Melinda Gates Foundation
Phase 1 has already been executed with the construction of temporary OPD, guest house and boundary wall and Phase 2 of the execution is being fast tracked
Investment in response to increased demand for North American-based chemistry services
AI-driven company anumana partnered with Novartis to drive the development of its electrocardiogram (ECG) AI algorithms to detect subclinical heart disease.
The total financial outlay of the scheme is Rs.500 crore for a period of five years from 2021-22 to 2025-26.
Subscribe To Our Newsletter & Stay Updated
